(PALI) Palisade Bio - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US6963894026
Stock:
Total Rating 37
Risk 33
Buy Signal 1.13
| Risk 5d forecast | |
|---|---|
| Volatility | 159% |
| Relative Tail Risk | -24.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.15 |
| Alpha | 96.88 |
| Character TTM | |
|---|---|
| Beta | -0.073 |
| Beta Downside | -0.891 |
| Drawdowns 3y | |
|---|---|
| Max DD | 98.98% |
| CAGR/Max DD | -0.62 |
EPS (Earnings per Share)
Revenue
Description: PALI Palisade Bio
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -11.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -1.45 > 0.02 and ΔFCF/TA -10.10 > 1.0 |
| NWC/Revenue: 83.8k% < 20% (prev 2476 %; Δ 81.3k% < -1%) |
| CFO/TA -1.45 > 3% & CFO -10.1m > Net Income -11.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (7.47m) vs 12m ago 28.46% < -2% |
| Gross Margin: 0.0% > 18% (prev 0.77%; Δ -77.20% > 0.5%) |
| Asset Turnover: 0.05% > 50% (prev 2.68%; Δ -2.63% > 0%) |
| Interest Coverage Ratio: -1019 > 6 (EBITDA TTM -11.3m / Interest Expense TTM 11.0k) |
Altman Z'' -15.00
| A: 0.48 (Total Current Assets 6.83m - Total Current Liabilities 3.48m) / Total Assets 6.97m |
| B: -20.63 (Retained Earnings -143.8m / Total Assets 6.97m) |
| C: -1.37 (EBIT TTM -11.2m / Avg Total Assets 8.15m) |
| D: -38.22 (Book Value of Equity -143.7m / Total Liabilities 3.76m) |
| Altman-Z'' Score: -113.5 = D |
Beneish M 1.00
| DSRI: 11.72 (Receivables 18.0k/96.0k, Revenue 4000 /250.0k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.22 (AQ_t 0.01 / AQ_t-1 0.04) |
| SGI: 0.02 (Revenue 4000 / 250.0k) |
| TATA: -0.16 (NI -11.2m - CFO -10.1m) / TA 6.97m) |
| Beneish M-Score: 4.46 (Cap -4..+1) = D |
What is the price of PALI shares?
As of February 26, 2026, the stock is trading at USD 1.90 with a total of 4,793,248 shares traded.
Over the past week, the price has changed by +12.43%, over one month by +4.97%, over three months by -11.63% and over the past year by +113.48%.
Over the past week, the price has changed by +12.43%, over one month by +4.97%, over three months by -11.63% and over the past year by +113.48%.
Is PALI a buy, sell or hold?
Palisade Bio has received a consensus analysts rating of 4.67.
Therefore, it is recommended to buy PALI.
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PALI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13.4 | 605.3% |
| Analysts Target Price | 13.4 | 605.3% |
PALI Fundamental Data Overview February 21, 2026
P/S = 14.0311
P/B = 76.2284
Revenue TTM = 4000 USD
EBIT TTM = -11.2m USD
EBITDA TTM = -11.3m USD
Long Term Debt = 90.0k USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 211.0k USD (from shortTermDebt, last quarter)
Debt = 211.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -5.02m USD (from netDebt column, last quarter)
Enterprise Value = 238.2m USD (243.2m + Debt 211.0k - CCE 5.23m)
Interest Coverage Ratio = -1019 (Ebit TTM -11.2m / Interest Expense TTM 11.0k)
EV/FCF = -23.62x (Enterprise Value 238.2m / FCF TTM -10.1m)
FCF Yield = -4.23% (FCF TTM -10.1m / Enterprise Value 238.2m)
FCF Margin = -252.1k% (FCF TTM -10.1m / Revenue TTM 4000 )
Net Margin = -280.6k% (Net Income TTM -11.2m / Revenue TTM 4000 )
Gross Margin = 0.0% ((Revenue TTM 4000 - Cost of Revenue TTM 4000 ) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 34.16 (Enterprise Value 238.2m / Total Assets 6.97m)
Interest Expense / Debt = 2.37% (Interest Expense 5000 / Debt 211.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -8.86m (EBIT -11.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.96 (Total Current Assets 6.83m / Total Current Liabilities 3.48m)
Debt / Equity = 0.07 (Debt 211.0k / totalStockholderEquity, last quarter 3.21m)
Debt / EBITDA = 0.45 (negative EBITDA) (Net Debt -5.02m / EBITDA -11.3m)
Debt / FCF = 0.50 (negative FCF - burning cash) (Net Debt -5.02m / FCF TTM -10.1m)
Total Stockholder Equity = 4.66m (last 4 quarters mean from totalStockholderEquity)
RoA = -137.7% (out of range, set to none)
RoE = -240.7% (Net Income TTM -11.2m / Total Stockholder Equity 4.66m)
RoCE = -235.9% (out of range, set to none) (EBIT -11.2m / Capital Employed (Equity 4.66m + L.T.Debt 90.0k))
RoIC = -184.0% (out of range, set to none) (NOPAT -8.86m / Invested Capital 4.81m)
WACC = 5.64% (E(243.2m)/V(243.4m) * Re(5.64%) + D(211.0k)/V(243.4m) * Rd(2.37%) * (1-Tc(0.21)))
Discount Rate = 5.64% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -10.20%
[DCF] Fair Price = unknown (Cash Flow -10.1m)
EPS Correlation: -4.25 | EPS CAGR: -7.50% | SUE: 0.21 | # QB: 0
Revenue Correlation: -11.22 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.04 | Chg7d=+0.000 | Chg30d=+0.005 | Revisions Net=+0 | Analysts=3
EPS next Year (2026-12-31): EPS=-0.23 | Chg7d=+0.000 | Chg30d=-0.010 | Revisions Net=-1 | Growth EPS=+56.9% | Growth Revenue=+0.0%
P/B = 76.2284
Revenue TTM = 4000 USD
EBIT TTM = -11.2m USD
EBITDA TTM = -11.3m USD
Long Term Debt = 90.0k USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 211.0k USD (from shortTermDebt, last quarter)
Debt = 211.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -5.02m USD (from netDebt column, last quarter)
Enterprise Value = 238.2m USD (243.2m + Debt 211.0k - CCE 5.23m)
Interest Coverage Ratio = -1019 (Ebit TTM -11.2m / Interest Expense TTM 11.0k)
EV/FCF = -23.62x (Enterprise Value 238.2m / FCF TTM -10.1m)
FCF Yield = -4.23% (FCF TTM -10.1m / Enterprise Value 238.2m)
FCF Margin = -252.1k% (FCF TTM -10.1m / Revenue TTM 4000 )
Net Margin = -280.6k% (Net Income TTM -11.2m / Revenue TTM 4000 )
Gross Margin = 0.0% ((Revenue TTM 4000 - Cost of Revenue TTM 4000 ) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 34.16 (Enterprise Value 238.2m / Total Assets 6.97m)
Interest Expense / Debt = 2.37% (Interest Expense 5000 / Debt 211.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -8.86m (EBIT -11.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.96 (Total Current Assets 6.83m / Total Current Liabilities 3.48m)
Debt / Equity = 0.07 (Debt 211.0k / totalStockholderEquity, last quarter 3.21m)
Debt / EBITDA = 0.45 (negative EBITDA) (Net Debt -5.02m / EBITDA -11.3m)
Debt / FCF = 0.50 (negative FCF - burning cash) (Net Debt -5.02m / FCF TTM -10.1m)
Total Stockholder Equity = 4.66m (last 4 quarters mean from totalStockholderEquity)
RoA = -137.7% (out of range, set to none)
RoE = -240.7% (Net Income TTM -11.2m / Total Stockholder Equity 4.66m)
RoCE = -235.9% (out of range, set to none) (EBIT -11.2m / Capital Employed (Equity 4.66m + L.T.Debt 90.0k))
RoIC = -184.0% (out of range, set to none) (NOPAT -8.86m / Invested Capital 4.81m)
WACC = 5.64% (E(243.2m)/V(243.4m) * Re(5.64%) + D(211.0k)/V(243.4m) * Rd(2.37%) * (1-Tc(0.21)))
Discount Rate = 5.64% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -10.20%
[DCF] Fair Price = unknown (Cash Flow -10.1m)
EPS Correlation: -4.25 | EPS CAGR: -7.50% | SUE: 0.21 | # QB: 0
Revenue Correlation: -11.22 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.04 | Chg7d=+0.000 | Chg30d=+0.005 | Revisions Net=+0 | Analysts=3
EPS next Year (2026-12-31): EPS=-0.23 | Chg7d=+0.000 | Chg30d=-0.010 | Revisions Net=-1 | Growth EPS=+56.9% | Growth Revenue=+0.0%